Application of hararine or derivative thereof in preparation of medicine for treating thrombocytopenia
By promoting bone marrow megakaryocyte differentiation and platelet generation by using Haarmin or its derivatives, the problem of limited efficacy in the treatment of thrombocytopenia in the prior art is solved, and the recovery of platelet levels is achieved, and due to its natural source, low cost and side effects are achieved. Small.
Patent Information
- Application Number
- CN202411131359.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-17
- Publication Date
- 2024-11-15
AI Technical Summary
The prior art has limited effect in the treatment of thrombocytopenia caused by acute radiation syndrome and is difficult to prevent side effects. There has been no research on the treatment effect of Halmine on such symptoms and its mechanism of action.
Use Haar base or its derivatives as active ingredients, combined with pharmaceutically acceptable excipients to prepare injection or oral preparations for the treatment of aplastic anemia, thrombocytopenia, coagulation disorders and immune thrombocytopenic purpura, by promoting Megakaryocyte differentiation and maturation and platelet generation in the bone marrow.
Haarmin significantly restored the platelet level of irradiated thrombocytopenia mice in vivo, promoted the differentiation and polyploidization of megakaryocytes, showed the effect of treating thrombocytopenia, and because it is widely present in natural Chinese herbal medicines In the meantime, the cost is lower and the side effects are small.
Smart Images

Figure CN118948845A_ABST
Abstract
Description
Technical Field
[0001] The invention relates to use of halidine or its derivatives in preparing medicines for treating thrombocytopenia, belonging to the field of medicines. Background Art
[0002] In acute radiation syndrome, thrombocytopenia (RIT) is associated with high morbidity and mortality. 9 / L is called thrombocytopenia. Radiotherapy, as an effective treatment for tumors, can kill stromal cells and destroy the hematopoietic microenvironment, which will hinder the platelet production process. The corresponding means of treating thrombocytopenia and promoting the differentiation of bone marrow megakaryocytes are: first, platelet transfusion; second, platelet-promoting growth factors, such as recombinant human thrombopoietin and recombinant human interleukin-11; third, thrombopoietin receptor agonists, such as eltrombopag and romiplostim; fourth, immunotherapy, such as glucocorticoids and mesenchymal cells; and finally, other treatments, such as plasma exchange and decitabine. However, the above treatments are very limited in effect, and side effects are difficult to prevent.
[0003] Harmine (HM) is an alkaloid in the seeds of the medicinal plant Peganumharmala L. of the family Triplus terrestris. Harmine has multiple pharmacological activities, including anti-inflammatory, neuroprotective, cardiovascular protective, anti-diabetic and anti-tumor activities, etc. Most importantly, in the cardiovascular system, harmine can dilate blood vessels, promote blood circulation, improve vascular toughness and elasticity, and is associated with collagen-induced platelet aggregation. CN202111369681.5, Invention Name: Use of β-carboline alkaloid harmine in the diagnosis of Alzheimer's disease, discloses the use of β-carboline alkaloid harmine in the diagnosis of Alzheimer's disease. CN201210425885.0, Invention Name: Use of dehydrogenated harmine derivatives in the preparation of antibacterial drugs, discloses the use of dehydrogenated harmine derivatives in the preparation of antibacterial drugs. Application number 202211205683.5, invention name: Use of harmaline in the preparation of drugs for preventing and / or treating new bunyavirus infectious diseases, discloses the use of harmaline in the preparation of drugs for preventing and / or treating new bunyavirus infectious diseases. This application only discloses the antiviral effect of harmaline, wherein the new bunyavirus is the fever with thrombocytopenia syndrome virus. Fever with thrombocytopenia syndrome (SFTS) is an acute natural zoonosis caused by SFTSV. It is mainly transmitted to humans through tick bites. The clinical characteristics are fever and thrombocytopenia. A small number of patients are in critical condition and rapidly develop into severe and critical conditions, and may eventually die from multiple organ failure.
[0004] Thrombocytopenia is the main clinical manifestation or common complication of many diseases. Reduced platelet production, excessive destruction or consumption, and abnormal distribution are the main causes of thrombocytopenia. Thrombocytopenia is caused by many reasons, such as immune factors, reduced bone marrow production, and splenomegaly. Its clinical manifestations are mainly skin and mucous membrane bleeding and difficulty in stopping bleeding. So far, there has been no literature reporting the therapeutic effect of halidine on thrombocytopenia caused by radiotherapy and chemotherapy and its mechanism of action. Summary of the invention
[0005] The invention provides a new use of halidine.
[0006] The present invention provides the use of halidine or its derivatives in preparing a drug for treating thrombocytopenia;
[0007] The structural formula of the described Hal alkali is:
[0008]
[0009] Wherein, the medicine is a medicine for treating thrombocytopenia caused by aplastic anemia.
[0010] Wherein, the drug is a drug for restoring the platelet level in patients with thrombocytopenia.
[0011] The drug is a drug that promotes the differentiation, maturation and polyploidy of megakaryocytes in the bone marrow of hematopoietic tissue.
[0012] The present invention also provides the use of halidine or its derivatives in the preparation of drugs for treating coagulation disorders, essential thrombocythemia, and immune thrombocytopenic purpura. The drug is prepared from halidine as an active ingredient and pharmaceutically acceptable excipients or auxiliary ingredients to form a commonly used pharmaceutical preparation.
[0013] Wherein, the preparation is an injection preparation or an oral preparation.
[0014] Wherein, the oral preparations are tablets, capsules, pills, granules, and oral liquids.
[0015] The beneficial effects of the present invention are:
[0016] Through a large number of experimental investigations by the inventors, it was found that Harrine had no effect on the cytotoxicity and cell viability of megakaryocytes in vitro, and had a certain activity in promoting differentiation, maturation and proplatelet production of megakaryocytes in vitro; at the same time, the study found that Harrine had a promoting effect on platelet production in vivo, could restore the platelet level of irradiated thrombocytopenic mice, and promote the differentiation, maturation and polyploidy of megakaryocytes in the bone marrow, the main hematopoietic tissue. It can be seen that Harrine has a certain effect in the treatment of thrombocytopenia, and Harrine is widely present in natural Chinese medicinal materials, with low cost and few side effects. BRIEF DESCRIPTION OF THE DRAWINGS
[0017] Figure 1 The figure shows the effect of Harpine on the platelet level in irradiation-induced thrombocytopenia mice (*P<.05, **P<.01, ***P<.001 compared with the model group);
[0018] Figure 2 The figure shows the effect of halidine on the MPV level in irradiated thrombocytopenic mice (*P<.05, **P<.01, ***P<.001 compared with the model group);
[0019] Figure 3 This is a graph showing the effect of Hartine on the expression of CD41 / CD61 in bone marrow cells of mice with irradiated thrombocytopenia;
[0020] Figure 4 Statistical analysis of the effect of Hart's alkaloids on the expression of CD41 / CD61 in bone marrow cells of mice with thrombocytopenia induced by irradiation (*P<.05, **P<.01, ***P<.001 compared with the model group);
[0021] Figure 5 The effect of haridine on the expression of CD41 / CD61 in spleen cells of irradiated thrombocytopenic mice;
[0022] Figure 6 This is a statistical analysis of the effect of harpine on the expression of CD41 / CD61 in spleen cells of mice with thrombocytopenia induced by irradiation (*P<.05, **P<.01, ***P<.001 compared with the model group);
[0023] Figure 7 This is a graph showing the effect of harpine on the expression of CD41 / CD61 in lung cells of mice with irradiated thrombocytopenia;
[0024] Figure 8 This is a statistical analysis of the effect of harpine on the expression of CD41 / CD61 in lung cells of mice with irradiated thrombocytopenia (*P<.05, **P<.01, ***P<.001 compared with the model group);
[0025] Fig. 9 This is the result of H&E staining of bone marrow cells of mice with thrombocytopenia induced by irradiation with Hart's alkali;
[0026] Fig.10 Statistical analysis of the effect of Hart's alkaloids on H&E staining of bone marrow cells in mice with irradiated thrombocytopenia (*P<.05, **P<.01, ***P<.001 compared with the model group);
[0027] Fig.11 This is the result of H&E staining of spleen cells of irradiated thrombocytopenic mice by haridine;
[0028] Fig.12 This is a statistical analysis of the effect of harpine on H&E staining of spleen cells in mice with irradiated thrombocytopenia (*P<.05, **P<.01, ***P<.001 compared with the model group);
[0029] Fig.13 This is a microscopic photograph of the effect of Har alkaloids on the differentiation of Meg-01 cells;
[0030] Fig.14 This is the quantitative result of the effect of Harrine on the differentiation of Meg-01 cells (*P<.05, **P<.01, ***P<.001 compared with the control group);
[0031] Fig.15 This is a microscopic photograph of the effect of Hart alkaloids on HEL cell differentiation;
[0032] Fig.16 This is the quantitative result of the effect of Harrine on HEL cell differentiation (*P<.05, **P<.01, ***P<.001 compared with the control group);
[0033] Fig.17 The figure shows the effect of Harpine on CD41 / CD42b expression in Meg-01 cells on days 4 and 6;
[0034] Fig.18 Statistical analysis of CD41 / CD42b expression in Meg-01 cells on days 4 and 6 after treatment with harpine (*P<.05, **P<.01, ***P<.001 compared with the control group);
[0035] Fig.19 The figure shows the effect of Harpine on the ploidy of Meg-01 cells on the 4th and 6th days;
[0036] Fig. 20 Statistical analysis of the effect of Hartidine on the ploidy of Meg-01 cells on days 4 and 6 (*P<.05, **P<.01, ***P<.001 compared with the control group);
[0037] Fig.21 The Giemsa staining images of Meg-01 cells treated with Harpine on the 4th and 6th days;
[0038] Fig. 22 These are Giemsa staining images of HEL cells treated with Harpine on the 4th and 6th days;
[0039] Fig.23 The phalloidin staining images of Meg-01 cells on the 4th and 6th days after the intervention of Harpine;
[0040] Fig.24 The phalloidin staining images are shown on the 4th and 6th days after the intervention of Harpine on HEL cells;
[0041] Fig.25 The effect of different concentrations of Harpine on the cytotoxicity of Meg-01 cells. (*Compared with the control group, *P<.05, **P<.01, ***P<.001);
[0042] Fig.26 The effect of different concentrations of Hartidine on HEL cell toxicity. (*Compared with the control group, *P<.05, **P<.01, ***P<.001)
[0043] Fig. 27 The effect of different concentrations of Harpine on LDH release in Meg-01 cells. (*Compared with the control group, *P<.05, **P<.01, ***P<.001);
[0044] Fig.28 Effects of different concentrations of Harrine on LDH release in HEL cells. (*P<.05, **P<.01, ***P<.001 compared with the control group). DETAILED DESCRIPTION
[0045] Experimental Example 1 In vivo pharmacodynamic study of Harmine (HM) on irradiated thrombocytopenia mice
[0046] 1. Experimental methods
[0047] Grouping and modeling: 72 Kunming mice aged 6-8 weeks were taken, half male and half female. After 7 days of adaptive feeding, 12 mice were reserved for the unirradiated control group, and the rest of the mice were irradiated with X-rays (4Gy) throughout the body. Blood was collected from the fundus venous plexus of the mice on the first day after irradiation, and the blood routine level was detected by Sysmex XT-2000iV blood cell analyzer. According to the baseline levels of PLT, RBC, and WBC, the irradiated model mice were randomly divided into a model group (only irradiated, no drug administration), a positive drug TPO group, a low-dose group of halidine (5 mg / kg, expressed as HM-L), a medium-dose group of halidine (10 mg / kg, expressed as HM-M), and a high-dose group of halidine (20 mg / kg, expressed as HM-H). The halidine is a commercially available product.
[0048] 1) Drug preparation and administration
[0049] Preparation of TPO: Take out 72 μL of 15000U / mL TPO, dilute to 4mL with physiological saline, store on ice away from light, and use it immediately. Preparation of Halidine: Take out 18mg of Halidine monomer powder, dissolve it with 9mL of physiological saline, add 2% DMSO and 1% Tween 80 to dissolve, and prepare it into 2mg / mL working solution, and use it immediately.
[0050] The unirradiated control group and the irradiated model group were intraperitoneally injected with 0.1 mL of normal saline per 10 g of mouse body weight; the positive drug TPO group was converted to 2700 U / kg based on the ratio of human (3000 U / kg) and mouse doses; the low-dose group (HM-L) of halidine was intraperitoneally injected with 5 mg / kg / d, the medium-dose group (HM-M) of halidine was intraperitoneally injected with 10 mg / kg / d, and the high-dose group (HM-L) of halidine was intraperitoneally injected with 20 mg / kg / d. The injection volume of all drug groups was 0.1 mL / 10 g. On the first day after blood collection and grouping (i.e., the second day after radiation), intraperitoneal injection was performed once a day, and the drug was continuously administered until the 16th day. From the beginning of modeling to the end of the experiment, the activity behavior, mental state, hair gloss, and death of the mice were observed daily. The mice were weighed regularly every 3 days, and the drug was administered according to the updated body weight.
[0051] 2) Sampling and detection index: On the 1st, 4th, 7th, 10th, 13th, and 16th day after the mice were irradiated, 40 μL of blood was collected from the orbital venous plexus of the mice, added to an EP tube pre-filled with 160 μL of diluent, gently blown and mixed, and the peripheral PLT and MPV levels were analyzed using a Sysmex XT-2000iV blood cell analyzer. On the 16th day of administration, the mice were killed by cervical dislocation, and the liver, spleen, kidney, and thymus were removed and weighed to calculate the organ index: organ index = organ weight (kg) / mouse body weight (kg). The femur of the mice was removed and fixed with 4% paraformaldehyde, and the number of megakaryocytes in the main hematopoietic tissue bone marrow was observed by H&E staining. The femur of the other side of the mouse was taken to collect bone marrow cells, which were centrifuged at 1500 rpm for 5 min at 4°C. The cells were resuspended in PBS, and CD41 and CD61 flow cytometry antibodies were added. The cells were incubated in the dark for 30 min, and the expression of CD41 / CD61 in bone marrow, spleen and lung megakaryocytes was detected and analyzed using flow cytometry.
[0052] 2. Experimental results
[0053] Experimental results: As shown in Table 1, the changes in the platelet level of mice showed that the platelet level of mice decreased rapidly after irradiation, and the initial decline rate was lower than that of the irradiation group. The platelet level reached the lowest on the 7th day after irradiation, but the platelet level of the positive drug TPO group and the halidine administration group (5 mg / kg, 10 mg / kg, 20 mg / kg, respectively expressed as HM-L, HM-M, HM-H) was higher than that of the model group (* compared with the model group, *P<.05, **P<.01, ***P<.001); then the platelet level gradually recovered, and the platelet level of the mice in the halidine administration group recovered faster than that in the model group. On the 13th day after irradiation, the platelet level of the positive drug TPO group and the halidine administration group The levels of platelets in the halidine-treated group and the model group were significantly increased (* compared with the model group, *P<.05, **P<.01, ***P<.001); on the 16th day, the platelets basically returned to normal levels and there were significant differences between the halidine-treated group and the model group (* compared with the model group, *P<.05, **P<.01, ***P<.001); as shown in Table 2, there was no significant change in the mean platelet volume (MPV) of mice. It can be seen from Tables 1 and 2 that halidine has a significant effect on the recovery of platelets, indicating that halidine has a significant therapeutic effect on mice with irradiation-induced thrombocytopenia.
[0054] Table 1 Effect of Hartine (HM) on platelet production in mice (*Compared with the model group, *P<.05, **P<.01, ***P<.001)
[0055]
[0056] Table 2 Effects of Hart's alkaloids (HM) on mouse MPV
[0057]
[0058]
[0059] 1) According to Figure 1 (platelet count) and Figure 2 (MPV statistics) shows that: Figure 1 ) Compared with the model group, the platelet levels of mice in the halidine administration group (5 mg / kg, 10 mg / kg, 20 mg / kg, respectively expressed as HM-L, HM-M, HM-H) and the positive drug TPO group increased significantly after the 13th day of modeling. Although it did not return to the level of the TPO administration group, the halidine administration group (HM-L, HM-M, HM-H) had shown a significant effect of restoring the platelet level (* compared with the model, *P<.05, **P<.01, ***P<.001), indicating that halidine has a certain therapeutic effect on irradiation-induced thrombocytopenia mice and has a significant effect on restoring the platelet level; ( Figure 2 ) Moreover, while halidine restored platelet levels, the mean platelet volume did not change significantly (*compared with the model, *P<.05, **P<.01, ***P<.001), indicating that halidine administration can promote platelet recovery without affecting the mean platelet volume, and can exert better efficacy at low doses.
[0060] 2) According to Figure 3-8 It can be seen that: Figure 3 , Figure 5 , Figure 7 (Results) and Figure 4 , Figure 6 , Figure 8 (Statistical analysis chart) shows that the FITC-CD41(+)-PE-CD61(+) positive area represents the surface markers CD41 and CD61 double positive area of megakaryocyte differentiation and maturation in the bone marrow, spleen and lung (CD41 is a specific surface antigen of megakaryocytes, expressed in the whole process of megakaryocyte differentiation; CD61 is a specific surface antigen of megakaryocytes, and its expression tends to be the earliest glycoprotein expressed in megakaryocytes, which is a single-chain surface membrane glycoprotein). Compared with the model group, the in vivo administration of halidine (20 mg / kg, expressed as HM-H) on the 16th day can significantly promote the expression of surface antigen CD41 / CD61 in the process of megakaryocyte differentiation, indicating that halidine can promote megakaryocyte differentiation in the bone marrow, spleen and lung; ( Figure 4 , Figure 6 , Figure 8 )right Figure 3 , Figure 5 , Figure 7The flow cytometry results were statistically analyzed. After 16 days of in vivo administration of halidine (20 mg / kg, expressed as HM-H), the expression rate of CD41(+) / CD61(+) in bone marrow cells, spleen cells and lung cells in the halidine-administered group (20 mg / kg, expressed as HM-H) was significantly increased compared with the model group on the 16th day, which was close to the differentiation of bone marrow, spleen and lung megakaryocytes in the normal control group mice, with statistical significance (*compared with the model group, *P<.05, **P<.01, ***P<.001), indicating that the in vivo administration of halidine can not only restore the platelet level, but also significantly stimulate the expression of surface antigens CD41 / CD61 of bone marrow, spleen and lung megakaryocytes. Therefore, halidine has a significant promoting effect on the differentiation of megakaryocytes in the bone marrow, spleen and lung, indicating that the hematopoietic effect of halidine is mainly concentrated in the bone marrow, spleen and lung hematopoiesis.
[0061] 3) According to Figure 9-12 It can be seen that: Fig. 9 , Fig.11 (Results) and Fig.10 , Fig.12 (Statistical analysis chart) shows that on the 16th day after the administration of halidine in vivo, compared with the model group, the halidine administration group (20 mg / kg, expressed as HM-H) and the positive drug TPO significantly increased the size and number of megakaryocytes in the bone marrow and spleen, among which the morphology and lobulation of megakaryocytes were not significantly different from those in the normal control group, indicating that the halidine administration group has the effect of promoting the restoration of megakaryocytes in the hematopoietic bone marrow and spleen to normal, and halidine promotes the proliferation and differentiation of megakaryocytes; the megakaryocytes in the bone marrow and spleen of the normal control group, model group, positive drug TPO group, and halidine administration group were significantly increased. The megakaryocytes in the bone marrow and spleen were counted and statistically analyzed. It was found that the megakaryocytes in the halidine-treated group (20 mg / kg, expressed as HM-H) showed an obvious increasing trend. Although the effect was not as obvious as that of the positive drug TPO group, it was significantly more than the megakaryocytes in the model group. In addition, with the increase of drug concentration, the number of megakaryocytes in the bone marrow and spleen tended to return to normal levels, indicating that halidine promoted the proliferation and differentiation of megakaryocytes in the bone marrow and spleen, confirming the above flow cytometry detection results (*Compared with the model group, *P<.05, **P<.01, ***P<.001).
[0062] Experimental Example 2 Effect of Harmine (HM) on Megakaryocyte Differentiation
[0063] 1. Experimental methods
[0064] Meg-01 cells and HEL cells were cultured in an incubator at 37°C and 5% CO2 using RPMI-1640 basal medium containing 10% FBS, 1% penicillin-streptomycin mixture, and the medium was changed every day. When the cell density reached 80-90%, the cells were subcultured at a ratio of 1:2.
[0065] Take Meg-01 cells and HEL cells with good growth status and place them in a 15 mL sterile centrifuge tube. Wash and resuspend them in phosphate buffered saline (PBS). Take 10 μL of the cell suspension and count it on a counting plate. Adjust the cell density to 2×10 4 / mL, 2×10 4 Each well was inoculated in a 12-well plate, 500 μL per well, and the experiment was set up as a control group (with cells, without halogen, with culture medium, 3 replicates), a positive drug PMA group (with cells, 500 μL of PMA-containing medium was added to the positive drug PMA group, the final concentration of PMA was 2.5 nM, with culture medium, 3 replicates), and a halogen-treated group (with cells, drug administration: 2.5 μM, 5 μM, with culture medium, 3 replicates). 500 μL of drug-containing medium was added to the halogen-treated group, and 500 μL of the same amount of medium was added to the control group. The final concentration of halogen was 2.5 μM and 5 μM, and it was routinely cultured in a 37°C, 5% CO2 incubator. After culturing for 4 days and 6 days, the following experiments were performed:
[0066] 1) Inverted microscope white light photography: Meg-01 cells and HEL cells were placed in a well plate, and the cells were magnified 100 times using an inverted microscope to collect pictures on the 4th and 6th days of intervention to observe the changes in cell morphology after drug administration and to count the number of megakaryocytes.
[0067] 2) Flow cytometry detection of CD41 / CD42b expression: Meg-01 cells were collected and centrifuged at 1500 rpm for 5 min, washed twice with pre-cooled PBS, mixed with 100 μL of PBS, centrifuged at 1500 rpm for 5 min, supernatant was aspirated, 3 μL of CD41 antibody and 3 μL of CD42b antibody were added, and the cells were placed on ice and protected from light for 15 min. 200-400 μL of PBS was added before injection, and the cells were detected at an excitation wavelength of 488 nm to detect the expression of surface markers CD41 / CD42b during megakaryocyte differentiation.
[0068] 2. Experimental results
[0069] The experimental results are as follows Figure 13-18 shown.
[0070] 1) According to Figure 13-16 It can be seen that: Fig.13 , Fig.17) Compared with the control group, after 4 and 6 days of intervention with Harrine in Meg-01 cells and HEL cells, at two time points, the positive drug PMA and gradient concentrations of Harrine (2.5μM, 5μM) showed the same effect of promoting megakaryocyte differentiation, which was specifically manifested by a significant increase in megakaryocytes (arrows), indicating that Harrine has the potential activity of promoting megakaryocyte differentiation; ( Fig.14 ) At the same time, the megakaryocytes in the control group, the positive drug PMA group, and the halidine administration group were semi-quantitatively counted. Fig.14 The left picture shows the semi-quantitative analysis results of Meg-01 cells on the 4th day. Fig.14 The right figure is the semi-quantitative analysis result on the 6th day; Statistical analysis found that the large cells in the halidine administration group (2.5μM, 5μM) showed a significant increase trend, ( Fig.16 ) Similarly, statistical analysis found that the number of large cells in the HEL cells also showed a significant increase in the halidine-treated groups (2.5 μM, 5 μM), indicating that halidine at concentrations of 2.5 μM and 5 μM has the activity of promoting megakaryocyte differentiation and presents a concentration-dependent trend (*Compared with the control group, *P<.05, **P<.01, ***P<.001).
[0071] 2) According to Figure 17-18 It can be seen that the FITC-CD41(+)-PE-CD42b(+) positive area represents the surface markers CD41 and CD42b double positive area of megakaryocyte differentiation and maturation (CD41 is a specific surface antigen of megakaryocytes, expressed in the whole process of megakaryocyte differentiation; CD42b is a specific surface antigen of megakaryocytes, and its expression tends to be more differentiated and more mature megakaryocytes. Its expression indicates the terminal maturation of the megakaryocyte system). Fig.17 ) Compared with the control group, the intervention of Hartine (2.5μM, 5μM) on the 4th and 6th days can significantly promote the expression of surface antigen CD41 / CD42b in the process of megakaryocyte differentiation, indicating that Hartine at a concentration of 2.5μM and 5μM can promote megakaryocyte differentiation; ( Fig.18) At the same time, the flow cytometry results on the 4th and 6th days were statistically analyzed. On the 4th day after the intervention of halidine (2.5μM, 5μM), the CD41(+) / CD42b(+) expression rate of Meg-01 cells treated with halidine was significantly increased, which was statistically significant (*compared with the control group, *P<.05, **P<.01, ***P<.001); on the 6th day after the intervention of halidine (2.5μM, 5μM), the CD41(+) / CD42b(+) expression rate of Meg-01 cells treated with halidine was significantly increased, and was higher than the expression level on the 4th day, which was statistically significant (*compared with the control group, *P<.05, **P<.01, ***P<.001), indicating that halidine can significantly stimulate the expression of Meg-01 cell surface antigen CD41 / CD42b.
[0072] Experimental Example 3 Effect of Harmine (HM) on Megakaryocyte Differentiation and Maturation
[0073] 1. Experimental methods
[0074] Meg-01 cells and HEL cells were cultured in an incubator at 37°C and 5% CO2 using RPMI-1640 basal medium containing 10% FBS, 1% penicillin-streptomycin mixture, and the medium was changed every day. When the cell density reached 80-90%, the cells were subcultured at a ratio of 1:2.
[0075] Take Meg-01 cells and HEL cells with good growth status and place them in a 15 mL sterile centrifuge tube. Wash and resuspend them in phosphate buffered saline (PBS). Take 10 μL of the cell suspension and count it on a counting plate. Adjust the cell density to 2×10 4 / mL, 2×10 4 Each well was inoculated in a 12-well plate, 500 μL per well, and the experiment was set up as a control group (with cells, without halogen, with culture medium, 3 replicates), a positive drug PMA group (with cells, 500 μL of PMA-containing medium was added to the positive drug PMA group, the final concentration of PMA was 2.5 nM, with culture medium, 3 replicates), and a halogen-treated group (with cells, drug administration: 2.5 μM, 5 μM, with culture medium, 3 replicates). 500 μL of drug-containing medium was added to the halogen-treated group, and 500 μL of the same amount of medium was added to the control group. The final concentration of halogen was 2.5 μM and 5 μM, and it was routinely cultured in a 37°C, 5% CO2 incubator. After culturing for 4 days and 6 days, the following experiments were performed:
[0076] 1) Flow cytometry for DNA ploidy expression: Meg-01 cells were collected on the 4th and 6th days after the intervention of Har alkaloids, washed once with PBS, centrifuged at 1500rpm for 5min, the supernatant was removed, 500μL of 70% pre-cooled ethanol was added to the cells, fixed for 2h-overnight, and stored at 4°C. After fixation, the fixative was washed off with PBS, and the supernatant was removed after centrifugation (1500rpm, 5min); 100μL RNaseA was added, resuspended, and bathed at 37°C for 30min; 400μL PI (protected from light, toxic), mixed, and incubated at 4°C for 30min. The red fluorescence at the excitation wavelength of 488nm was recorded and the expression of DNA ploidy was analyzed.
[0077] 2) Giemsa staining: Meg-01 cells and HEL cells after Harrine intervention were collected, centrifuged at 1500 rpm for 5 min, resuspended in pre-cooled PBS solution, added with an equal volume of 0.075 mol / L KCl solution for swelling, centrifuged at 1500 rpm for 2 min, fixed with fixative (methanol: glacial acetic acid = 3:1), and then Giemsa staining was performed to observe the cell morphological changes after Harrine intervention with gradient concentrations.
[0078] 3) Phalloidin staining: Meg-01 cells and HEL cells after halidine intervention were collected, centrifuged at 1500rpm for 5min, the supernatant was discarded, the cell pellet was retained, washed once with PBS, fixed with 4% paraformaldehyde for 10min, and the slides were spun. 0.5% TritonX-100 solution was used for permeabilization for 5min, and washed three times with PBS; the cells were covered with diluted phalloidin working solution, incubated at room temperature in the dark for 1h, and washed three times with PBS; DAPI counterstained the cell nucleus for 20s, and washed three times with PBS; after sealing, the cells were magnified 100 times using an inverted microscope to collect pictures.
[0079] 2. Experimental results
[0080] The experimental results are as follows Figure 19-24 shown.
[0081] 1) According to Fig.19 (Results) and Fig. 20 (Statistical analysis chart) shows that: Fig.19 ) When Meg-01 cells were treated with halidine (2.5μM, 5μM) for 4 days, the number of cells with ploidy>2N and>4N in the halidine-treated group was greater than that in the control group, and the ploidy of cells with ploidy>4N and above increased. Fig. 20) Statistical analysis of ploidy ratios, the upper figure is the semi-quantitative analysis results on the 4th day, and the lower figure is the semi-quantitative analysis results on the 6th day; compared with the control group, the proportion of DNA ploidy>2N in Meg-01 cells treated with halidine (2.5μM, 5μM) on the 4th and 6th days was significantly increased, and the expression level on the 6th day was higher than that on the 4th day, and the difference was statistically significant (*compared with the control group, *P<.05, **P<.01, ***P<.001), indicating that halidine can promote the maturation of polyploidy during megakaryocyte differentiation.
[0082] 2) According to Fig.21 and Fig. 22 It can be seen that: Giemsa staining results showed that at the 4th and 6th day time points of the intervention of Meg-01 cells and HEL cells with halidine, obvious mononuclear cells (light color is the cell membrane and dark color is the cell nucleus) could be seen in the control group. However, compared with the control group, there were significant differences in the nuclear lobation status of the positive drug PMA group and the halidine administration group (2.5μM, 5μM). The cells all showed multiple nuclear lobes, and the nuclear lobation status of the halidine administration group (2.5μM, 5μM) was similar to that of the positive drug PMA group, and the number of multinuclear cells increased significantly, indicating that halidine promotes the generation of polyploidy during megakaryocyte differentiation.
[0083] 3) According to Fig.23 and Fig.24 It can be seen that the results of phalloidin staining showed that at the 4th and 6th day of halidine intervention in Meg-01 cells and HEL cells, compared with the control group, the positive drug PMA group and the halidine administration group (2.5μM, 5μM) can significantly promote the expression of multinuclear fluorescence of megakaryocytes (red light TRITC Phalloidin is located in the cell membrane microfilament structure, and blue light DAPI is located in the cell nuclear structure), and the cell nucleus DAPI staining of the control group mostly showed a mononuclear state, and the cell nucleus DAPI staining of the drug administration group showed an obvious multinuclear lobed state, which was also expressed on the 4th and 6th day of halidine (2.5μM, 5μM) intervention, and with the increase of concentration, the multinuclear expression also showed an increasing trend, further indicating that halidine can promote the generation and maturation of polyploids in the process of megakaryocyte differentiation, and at the same time confirm the results of flow cytometry detection of DNA ploidy expression and Giemsa staining expression of polyploidy.
[0084] Experimental Example 4 Study on the Cytotoxicity and Cell Viability of Harmine (HM)
[0085] 1. Experimental methods
[0086] Meg-01 cells and HEL cells were cultured in an incubator at 37°C and 5% CO2 using RPMI-1640 basal medium containing 10% FBS, 1% penicillin-streptomycin mixture, and the medium was changed every day. When the cell density reached 80-90%, the cells were subcultured at a ratio of 1:2.
[0087] 1) Cytotoxicity assay: Take Meg-01 cells and HEL cells in good growth state and place them in a 15 mL sterile centrifuge tube. Wash and resuspend them in phosphate buffered saline (PBS). Take 10 μL of the cell suspension and count it on a counting plate. Adjust the cell density to 2×10 4 The cells were inoculated into a 96-well plate at 4000 cells / well, with 180 μL per well. The experimental settings were background group (without cells, without drugs, only culture medium), drug-containing background group (without cells, with drugs and culture medium), control group (with cells, without drugs, with culture medium), and halidine administration group (with cells, drug administration: 2.5 μM, 5 μM, 10 μM, 20 μM, 40 μM, with culture medium). 20 μL of drug-containing medium was added to the halidine administration group and drug-containing background group, and 20 μL of drug-free medium was added to the control group and background group. Three replicate wells were set for each group and routinely cultured in a 37°C, 5% CO2 incubator. After culturing for 1 day, 2 days, 3 days, 4 days, 5 days, and 6 days, the cell proliferation rate was detected by CCK8 method (Cell Counting Kit-8, Dojindo, specification: 100 mL / bottle, batch number: LZ735), and the experiment was repeated three times independently: 20 μL of CCK8 solution was dripped into each well, mixed, and incubated in the incubator for 1 hour, and then the absorbance OD value was detected at 490 nm. The final OD value = detection value - background group - drug-containing background group.
[0088] 2) Cell viability assay: Take Meg-01 cells and HEL cells in good growth state and place them in a 15 mL sterile centrifuge tube. Wash and resuspend them in phosphate buffered saline (PBS). Take 10 μL of the cell suspension and count it on a counting plate. Adjust the cell density to 2×10 4 / mL, 4000 cells / well were inoculated in a 96-well plate, 180μL per well, and the experiment was set up as a background group (no cells, no drugs, only culture medium), a drug-containing background group (no cells, containing drugs and culture medium), a control group, and a halidine administration group (2.5μM, 5μM, 10μM, 20μM, 40μM). 20μL of drug-containing medium was added to the halidine administration group and the drug-containing background group, and 20μL of drug-free medium was added to the control group and the background group. Three replicate wells were set up for each group and routinely cultured in a 37℃, 5% CO2 incubator. After culturing for 1day, 2day, 3day, 4day, 5day, and 6day, the LDH release detection kit was used: the culture plate was centrifuged at 1000rpm for 10 minutes, 150μL of supernatant was aspirated from each well, and added to another 96-well enzyme-linked detection plate. 20 μl 0.4 mol / L lactic acid solution, 20 μl 4 mmol / L 2-p-iodophenyl ester-3-p-chloronitrophenyl tetrazolium, and 20 μl reaction solution (PBS containing 0.03% BSA, 2.7 U / ml lipoamide dehydrogenase, 4.5 mmol / L hydrogenated coenzyme I (NAD+), and 1.2% sucrose) were added to each well of the second plate in sequence, and placed at room temperature for 20 minutes. The optical density (OD value) of each well was measured on an enzyme-linked detector, with a detection wavelength of 492 nm and a reference wavelength of 650 nm.
[0089] 2. Experimental results
[0090] The experimental results are as follows Figure 25-28 shown.
[0091] 1) According to Fig.25 , Fig.26 It can be seen that: compared with the control group (Control group), when Harpine (2.5μM, 5μM, 10μM, 20μM, 40μM) intervened in Meg-01 cells on the 4th day and intervened in HEL cells on the 3rd day, compared with the control group (Control group), Harpine at concentrations of 10μM, 20μM, and 40μM can significantly inhibit cell proliferation, but the survival rate of cells in the 2.5μM and 5μM Harpine-administered groups was equivalent to that of the Control group at each time point, indicating that Harpine at concentrations of 10μM, 20μM, and 40μM has certain toxicity to cells, but Harpine at concentrations of 2.5μM and 5μM has no toxicity to cells, and these two concentrations can be selected for subsequent experiments.
[0092] 2) According to Fig. 27 , Fig.28 It can be seen that: according to Fig.25 , Fig.26The experiment was carried out at the concentration obtained. After 2.5μM and 5μM Harrine intervened in Meg-01 cells and HEL cells respectively, compared with the control group (Control group), Harrine (2.5μM, 5μM) intervened in Meg-01 cells for six consecutive days. At the concentrations of 2.5μM and 5μM, the LDH release amounts of the Harrine-treated group and the Control group were basically the same, with no significant difference; similarly, Harrine (2.5μM, 5μM) intervened in HEL cells for four consecutive days. At the concentrations of 2.5μM and 5μM, the LDH release amounts of the Harrine-treated group and the Control group were basically the same, with no significant difference, indicating that the cell viability of the drug-treated group was equivalent to that of the control group, and Harrine (2.5μM, 5μM) had almost no effect on cell viability at this concentration.
[0093] The present invention provides a new use of halidine, namely, the use of halidine in the preparation of a drug for treating thrombocytopenia; through a large number of experimental investigations by the inventor, it is found that halidine has no effect on the cell viability of megakaryocytes in vitro, and has a certain activity in promoting differentiation, maturation and proplatelet production of megakaryocytes in vitro; at the same time, it is found that halidine has a promoting effect on platelet production in vivo, can restore the platelet level of patients with thrombocytopenia, and promote the differentiation, maturation and polyploidy of megakaryocytes in the main hematopoietic tissues of the bone marrow and spleen. It can be seen that halidine has a certain effect on the treatment of thrombocytopenia, and halidine is widely present in natural Chinese medicinal materials, with low cost and small side effects.
Claims
1. Use of halidine or its derivatives in the preparation of a drug for treating thrombocytopenia; The structural formula of the described Hal alkali is:
2. The use according to claim 1, characterized in that: The medicine is a medicine for treating thrombocytopenia caused by aplastic anemia.
3. The use according to claim 1 or 2, characterized in that: The drug is a drug for restoring the platelet level in patients with thrombocytopenia.
4. The use according to claim 1 or 2, characterized in that: The medicine is a medicine for promoting the differentiation, maturation and polyploidy of megakaryocytes in the bone marrow of hematopoietic tissue.
5. Use of halidine or its derivatives in the preparation of drugs for treating coagulation disorders, essential thrombocythemia, and immune thrombocytopenic purpura.
6. The use according to any one of claims 1 to 5, characterized in that: The medicine is prepared from halidine as the active ingredient and pharmaceutically acceptable excipients or auxiliary ingredients into a commonly used pharmaceutical preparation.
7. The use according to claim 6, characterized in that: The preparation is an injection preparation or an oral preparation.
8. The use according to claim 7, characterized in that: The oral preparations are tablets, capsules, pills, granules and oral liquids.
